Management of neutropenia with ENHERTU1

Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU.

  • Of the 491 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 68% of patients and 18% had Grade 3 or 4 decrease in neutrophil count. Febrile neutropenia was reported in 1.2% of patients
  • Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated
  • Based on the severity of neutropenia, manage through treatment interruption or dose reduction

Dose modifications for neutropenia1

Severity Treatment modification
Grade 3
(ANC less than 1.0 to 0.5 x 109/L)
  • Interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose
Grade 4
(ANC less than 0.5 x 109/L)

Toxicity grades are in accordance with NCI-CTCAE v.5.0.

Dose modifications for febrile neutropenia1

Severity Treatment modification
Absolute neutrophil count of less than 1.0 x 109/L and temperature greater than 38.3°C or a sustained temperature of ≥38°C for more than one hour

Toxicity grades are in accordance with NCI-CTCAE v.5.0.

Get ENHERTU Resources for You and Your Practice

An ENHERTU resource guide summarizing the efficacy and safety, dosing and administration, and recommendations for managing adverse reactions
Ready to learn more about ENHERTU?
ANC, absolute neutrophil count; HER2, human epidermal growth factor receptor 2; NCI-CTCAE, National Cancer Institute–Common Terminology Criteria for Adverse Events.